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The TAZ transcription co-activator promotes cell prolifera-
tion and epithelial-mesenchymal transition. TAZ is inhibited by
the Hippo tumor suppressor pathway, which promotes TAZ
cytoplasmic localization by phosphorylation. We report here
thatTAZprotein stability is controlled by a phosphodegron rec-
ognized by the F-box protein -TrCP and ubiquitylated by the
SCF/CRL1-TrCP E3 ligase. The interaction between TAZ and
-TrCP is regulatedby theHippopathway. Phosphorylationof a
phosphodegron in TAZ by LATS primes it for further phosphor-
ylation by CK1 and subsequent binding by -TrCP. There-
fore, the Hippo pathway negatively regulates TAZ function
by both limiting its nuclear accumulation and promoting its
degradation. The phosphodegron-mediated TAZ degrada-
tion plays an important role in negatively regulating TAZ
biological functions.
How tissue and organ size are controlled by coordinating cell
proliferation and apoptosis remains a fundamental question in
biology. Genetic screens in Drosophila over the last several
years have delineated a new signaling pathway, theHippo path-
way that regulates organ size by controlling both cell prolifera-
tion and apoptosis (1–3).Warts, the first identified component
of the Hippo pathway, is a Ser/Thr kinase and functions
together with its regulatory subunit, Mob, to inhibit tissue
growth (4). Acting upstream, Hippo (a Ste-20 kinase family
member) and its binding partner Sav phosphorylate and acti-
vate Warts (5, 6). Through a yet to be defined biochemical
mechanism, Merlin and expanded, two ERM (ezrin moesin
radixin) family members, stimulate the Hippo pathway and
are regulated by Fat, a transmembrane protocadherin family
member (7–10). Acting downstream of the Hippo pathway is
a transcriptional co-activator Yorkie, which regulates the
expression of a number of genes, including cyclin E and
Diap1 involved in cell proliferation and apoptosis, respectively
(11). Hence, theHippo pathway regulates organ size by control-
ling cell numbers.
The Hippo pathway is conserved from Drosophila to mam-
mals. Inmammalian cells, LATS1/2 andMST1/2 are the homo-
logues of DrosophilaWarts and Hippo, respectively (12). YAP,
the mammalian homologue of Drosophila Yorkie, has been
demonstrated to be phosphorylated and inhibited by LATS
(13). TAZ, first identified as a 14-3-3-binding protein, shares
50% sequence identity with YAP and has also been shown to
function as a transcriptional co-activator downstream of the
Hippo pathway (14, 15). TAZ is involved in the development of
multiple organs such as lung, fat, muscle, bone, limb, and heart
as well as many cellular processes including stem cell differen-
tiation, cell proliferation, epithelial mesenchymal transition
(EMT)4 (15–21). Taz knock-out mice develop two severe
abnormalities: polycystic kidney disease and emphysema (22,
23).
TAZ has also been implicated in human tumorigenesis. TAZ
is inhibited by the Hippo pathway, which contains well-estab-
lished human tumor suppressor NF2, the mammalian homo-
logue ofDrosophilaMerlin (15). In addition, other genes in the
Hippo pathway, such as WW45 and Mob, are known to be
mutated in human cancer cell lines (24, 25). Overexpression of
TAZ inMCF10Acells can promote cell proliferation, EMT, and
oncogenesis (15, 21, 26). Notably, elevated TAZ expression is
observed inmore than 20%of breast cancers, especially invasive
ductal carcinomas (21). Together, these findings suggest a
potential oncogenic activity of TAZ and the importance to con-
trol the level of TAZ for the normal development and tumor
suppression.
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We previously showed that the activity of TAZ is inhibited
by LATS kinase (15, 21). There are four HXRXXS LATS phos-
phorylation motifs in TAZ. We have demonstrated that phos-
phorylation of TAZ at Ser-89 by LATS promotes its interaction
with 14-3-3, resulting in cytoplasmic sequestration and func-
tional inhibition of TAZ. S89A mutation confers TAZ a partial
resistance to the inhibition by the Hippo pathway (15). Inter-
estingly, mutation of Ser-311 in another HXRXXS motif also
confers TAZ a partial resistance to LATS inhibition (15). The
functional significance and mechanism underlying the phos-
phorylation of Ser-311 and other HXRXXS motifs in TAZ reg-
ulation are not clear. This study is directed toward the mecha-
nism of phosphorylation in regulating TAZ ubiquitylation and
degradation.
In this report, we showed that phosphorylation of TAZ Ser-
311 by LATSprimes subsequent phosphorylation on Ser-314 in
the phosphodegron by CK1 and recruitment of the SCF-TrCP
E3 ubiquitin ligase, thus leads to TAZ ubiquitylation and deg-
radation. This provides a mechanism of temporal regulation of
TAZ by the Hippo pathway.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection—HEK293T cells were cul-
tured in Dulbecco’s modified Eagle’s medium (Invitrogen) sup-
plemented with10% fetal calf serum (HyClone), 100 units/ml
penicillin, and streptomycin (Invitrogen). MCF10A cells were
maintained in DMEM/F-12 medium (Invitrogen) supple-
mented with 5% horse serum (Invitrogen), 20 ng/ml epidermal
growth factor, 0.5 g/ml hydrocortisone, 10 g/ml insulin, 100
ng/ml cholera toxin, 100 units/ml penicillin, and streptomycin
(Invitrogen). Cell transfection was performed using Lipo-
fectamine 2000 (Invitrogen) or calcium phosphate method.
Cells were harvested at 24 h post-transfection for protein ana-
lyses. To establish stableTAZ-expressing cells, pBabe-TAZ ret-
roviruses were generated and used to infect MCF10A cells or
NIH3T3 and stable pools were selected in puromycin (1
g/ml)-containing media for 5 days.
Western Blotting Analysis—Protein lysates were prepared by
lysingMCF10Acells in a buffer containing 50mMTris-HCl (pH
8.0), 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% Nonidet
P-40, 1 mM EDTA, 1 mM PMSF, 25 mM NaF, and mixture pro-
tease inhibitors (Roche). Cell lysate (40 g) was resolved by
SDS-PAGE, followed by Western blotting analysis. Antibodies
of Flag (cat. A00170 fromGenScript or cat. A2220 from Sigma),
TAZ (cat. 560235 from BD), HA(F7) (Santa Cruz Biotechnol-
ogy, SC7392), c-Myc(9E10) (Santa Cruz Biotechnology, SC40),
and -actin (13E5, cat. 4970; Cell Signaling) were purchased
commercially. PhosphoTAZ antibody was raised in rabbits
using synthetic phosphopeptide as an antigen.
For immunoprecipitation experiments, 500 g of cell lysate
was incubated with anti-Flag M2-agarose for 2h at 4 °C. Beads
were washed three times with lysis buffer and centrifuged at
5,000 g for 5min between eachwash. Proteinwas eluted from
beads with 50 l of Laemmli sample buffer (Bio-Rad). Lysates
were resolved on 8% or 10% SDS-PAGE gels and transferred
onto nitrocellulose (Bio-Rad) for Western blotting.
Immunoprecipitation and Kinase Assay—293T cells were
transfected with HA-LATS2. 36-h post-transfection, cells were
lysed with lysis buffer (50 mMHEPES (pH 7.5), 150 mMNaCl, 1
mM EDTA, 1% Nonidet P-40, 50 mM NaF, 1.5 mM Na3VO4,
protease inhibitor mixture (Roche), 1 mM DTT, 1 mM PMSF),
and immunoprecipitated with anti-HA antibody. The immu-
noprecipitates were washed three times with lysis buffer, fol-
lowed once with washing buffer (40 mMHEPES, 200 mMNaCl)
and once with kinase assay buffer (30mMHEPES, 50mM potas-
sium acetate, 5 mM MgCl2). The immunoprecipitated LATS2
was subjected to kinase assays in the presence of 500 M cold
ATP, and 1 g of His-TAZ, which was expressed and purified
from Escherichia coli, as a substrate. The reaction mixtures
were incubated at 25 °C for 50 min and terminated with SDS
sample buffer. Phosphorylation was detected by either autora-
diograph or Western blotting with the phosphoTAZ specific
antibody.
In Vitro Ubiquitin Ligation Assays—Myc-tagged CUL1/
Skp1/Roc1/-TrCP1 plasmids were cotransfected into 293T
cells, and purified by anti-Myc antibody (Santa Cruz Biotech-
nology). His-tagged TAZ protein was purified in E. coli. For in
vitro ubiquitin ligation assays, TAZ protein was mixed with
Myc-CUL1/Skp1/Roc1/-TrCP1 in 30 l of ubiquitin ligation
buffer (50 mM Tris-HCl, pH 7.4, 5 mMMgCl2, 2 mMNaF, 2 mM
ATP, 10 nM okadaic acid, 0.6 mM DTT, 12 g of bovine ubiq-
uitin, 1 g of FLAG-tagged ubiquitin (Sigma), 60 ng of E1, 500
ng of E2), incubated at 37 °C for 1 h, then terminated by boiling
at 99 °C with SDS sample buffer for 5min. Western blotting
with anti-FLAG antibody was performed to examine the ubiq-
uitin ladders.
Wound Healing Assay—Monolayer cells were wounded with
a sterile plastic tip. Cell migration was observed by microscopy
16 h later.
Colony Formation Assay—Colony formation assay was per-
formed with NIH3T3 fibroblasts. TAZ mutant stable NIH3T3
(5  103) cells were seeded on 6-well plates and maintained in
DMEM supplemented with 10% fetal bovine serum for 2–3
weeks. Cells were fixed with 10% acetic acid and 10%methanol,
and then colonies were stained with 0.005% crystal violet.
RESULTS
TAZ Stability Is Regulated by the 26 S Proteasome—Elevated
TAZ protein levels in invasive ductal breast cancers led us to
examine the regulation of TAZprotein stability. To test this, we
treated HeLa andMCF10A cells with a protein synthesis inhib-
itor, cycloheximide (CHX), and measured the half-life of
endogenous TAZ. We found that TAZ is an unstable protein
with a half-life less than 2 h (Fig. 1A). Treatment of several
additional cell lines by MG132 also increased the steady state
levels of TAZ protein albeit by varying degrees (Fig. 1B). The
differential sensitivity of TAZ protein levels to MG132 treat-
ment is likely due to the difference in TAZ stability in those cell
lines. Collectively, our data suggest that TAZ protein stability is
regulated by the proteasome pathway.
TAZ Interacts with Components of SCF-TrCP E3 Ligase
Complex—Proteasome-mediated degradation depends on poly-
ubiquitylation of target protein. A direct interaction between the
E3 ubiquitin ligase and target protein dictates the selective
polyubiquitylation of the target protein. To search for TAZ-
interacting proteins, we performedmass spectrometry analysis
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of affinity-purified TAZ (26). One candidate TAZ-interacting
protein identified in this search was -TrCP, of which two pep-
tides, VIVTGSSDSTVR and LVVSGSSDNTIR, were identified
(supplemental Fig. S1). -TrCP, a F-box protein, is the sub-
strate binding subunit of the SKP1-CUL1-F-box (SCF-TrCP) E3
ubiquitin ligase andhas been implicated in degradation ofmany
growth promoting proteins, such as -catenin (27). To confirm
the interaction between TAZ and SCF-TrCP E3 ligase complex,
we performed co-immunoprecipitation (co-IP) experiments
and found that HA--TrCP could be readily pulled down by
TAZ (Fig. 1C). Similarly, reciprocal co-IP experiments also
showed that TAZ was co-precipitated with -TrCP (Fig. 1D).
Tian et al. (28) had previously reported a binding of TAZ
with -TrCP and suggested that TAZmediated the interaction
of PC2, a calcium-permeable cation channel protein polycystin
2, with and degradation by SCF-TrCP. The authors also noted
that SCF-TrCP affected TAZ protein levels. Given that TAZ
is an unstable protein, we considered TAZ as a substrate of
FIGURE 1. TAZ is an unstable protein associated with -TrCP. A, TAZ is an unstable protein. Both HeLa and MCF10A cells were treated CHX (20 g/ml) for
indicated times. Endogenous TAZ protein levels were determined. Relative TAZ levels were quantified by the ratio of TAZ to actin. B, MG132 increases TAZ
protein levels in multiple cell lines. Cells were treated with either solvent DMSO or 10 M MG132. Cell lysates were analyzed by Western blot (WB). Relative TAZ
levels were normalized by actin and quantified by the ratio between with and without MG132 treatment. C and D, TAZ binds to -TrCP. HA--TrCP was
co-transfected with FLAG-TAZ into HEK293T cells as indicated. -TrCP and TAZ associations were examined by reciprocal co-IP as indicated. E, Cullin-1
expression decreases TAZ protein levels. TAZ was co-transfected with different cullins as indicated. The steady state level of TAZ was determined by WB.
F, -TrCP knockdown increases TAZ protein levels. Three -TrCP RNAi oligos were individually transfected into 293 cells as indicated. -TrCP and TAZ levels
were determined by WB. Relative TAZ level were quantified by the ratio of TAZ to actin.
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SCF-TrCP, rather than a substrate
recruiter for PC2. To this end, we
first examined the effect of overex-
pression of different cullin family
members on the steady state level of
TAZ. Of six cullins examined, over-
expression of CUL1, but not the
other five cullins, dramatically
decreased TAZ protein level (Fig.
1E). We also examined the effect of
-TrCP knockdown on TAZ protein
levels. Among the three siRNA
tested, two significantly reduced
-TrCP protein and concomitantly
increased endogenous TAZ protein
levels (Fig. 1F). These data support a
notion that TAZ is a substrate of
SCF-TrCP E3 ligase, which utilizes
CUL1.
Phosphorylation of TAZ Ser-311
by LATS Is Important for -TrCP
Binding—TAZ contains two puta-
tive SCF-TrCP recognition phos-
phodegrons (28), one in the N-ter-
minal region and the other in the
C-terminal (Fig. 2A). Interestingly,
there are LATS phosphorylation
HXRXXS motifs in close proximity
to both putative phosphodegrons.
We testedwhether LATSmay affect
TAZ protein stability. We observed
that expression of LATS2 wild-type
(WT) significantly decreased the
steady state level of endogenous
TAZwhile expression of the kinase-
dead LATS2-K/R mutant modestly
increased TAZ protein level (Fig. 2B
and supplemental Fig. S2), support-
ing that TAZ phosphorylation by
LATS promotes its degradation. To
investigate the role of endogenous
LATS in the regulation of TAZ sta-
bility, we used shRNA to knock-
down LATS inHeLa cells and found
that silencing LATS2 significantly
increased endogenous TAZ protein
level (Fig. 2C). These data demon-
strate a role of LATS2 in promoting
TAZ degradation.
The binding between -TrCP
and its substrate proteins strongly
depends on the phosphorylation of
target proteins. We then tested the
role of the four putative LATS phos-
phorylation sites (Ser-66, Ser-89,
Ser-117, and Ser-311) in the binding
of TAZ with -TrCP. Individual
phosphorylation mutants, S66A,
FIGURE 2. Phosphorylation of Ser-311 is important for TAZ to bind with -TrCP. A, schematic illustration of TAZ
structure showing the two putative phosphodegrons. The sequences surrounding the phosphodegrons are shown.
Lats phosphorylation serine residues are indicated in gray. B, ectopic expression of LATS2 decreases the steady state
level of TAZ. The indicated plasmids were co-transfected into HEK293 cells. K/R denotes the kinase inactive mutant
LATS2. Relative TAZ levels were quantified by the ratio of TAZ to actin. C, LATS2 knocking down increases endoge-
nous TAZ protein level. LATS2 or unrelated control shRNA was transfected into 293 cells, and endogenous TAZ
protein level was examined. LATS2 knockdown efficiency was determined by WB. Relative TAZ levels were quanti-
fied by the ratio of TAZ to actin. D, mutation of the LATS phosphorylation site S311A disrupts the interaction
between TAZ and -TrCP. -TrCP was co-transfected with TAZ WT or different mutants. FLAG-TAZ was immuno-
precipitated and the associated HA--TrCP was detected by HA WB. The TAZ S311A mutant showed weak interac-
tion with -TrCP. E, mutations of the C-terminal phosphodegron disrupt the binding between TAZ and -TrCP.
Experiments were similar to those in panel D. Different TAZ mutants used in the transfection are indicated. F, Ser-311
is phosphorylated by LATS in vitro. His-TAZ and S311A mutant were expressed in E. coli and purified. HA-LATS2 was
immunoprecipitated from transfected 293T cells and used to phosphorylate the purified His-TAZ in vitro. Phos-
phorylation of TAZ was detected by pTAZ (Ser-311) antibody. His-TAZ was shown by Coomassie Blue staining.
G, expression of LATS enhances TAZ Ser-311 phosphorylation in transfected cells. TAZ WT or S311A mutant was
co-transfected with WT or kinase inactive (K/R) mutant of LATS2. Phosphorylation of the co-transfected TAZ was
detected by the pTAZ(311) antibody. H, MST/LATS co-transfection increases the interaction between TAZ and
-TrCP. Indicated plasmids were co-transfected into HEK293 cells. FLAG--TrCP was immunoprecipitated with FLAG
antibody and the co-precipitated HA-TAZ was detected by HA WB. I, TAZ protein level decreases with cell density.
MCF10A cells were cultured from 30% density to confluent. TAZ protein levels were determined by WB. J, leptomy-
cin B treatment results in a detectable increase of TAZ stability. Both Hela and Flag-TAZ expressed MCF10A cells were
pretreated with or without 20 nM leptomycin B for 5 h, followed by treatment with CHX (20 g/ml) for indicated
times. Endogenous or Flag-TAZ protein levels were determined.
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S89A, S117A, and S311A, were co-transfected with -TrCP
into HEK293 cells. Co-IP experiments showed that S66A,
S89A, and S117A mutants had little effect on -TrCP binding
(Fig. 2D). In contrast, S311Amutation substantially diminished
the interaction between TAZ and -TrCP. These results sug-
gest that the C-terminal phosphodegron plays an important
role inmediating TAZ bindingwith-TrCP and is regulated by
the phosphorylation at Ser-311.
Ser-314, situated in close proximity to the LATS phosphory-
lation site Ser-311, is predicted to play a critical role in mediat-
ing the binding of TAZ to -TrCP based on previous structure
and function studies on the interaction between -TrCP and
other phosphodegrons (29). To further test the role of the
C-terminal phosphodegron in-TrCP binding, we constructed
TAZS314A mutant and TAZD313A/G315A (referred to as DG
hereafter) double mutant, and examined their binding with
-TrCP. Consistent with previous observation (28), we found
that both S314A and DG mutants disrupted the interaction
between TAZ and -TrCP (Fig. 2E), demonstrating the func-
tional importance of the C-terminal phosphodegron in medi-
ating the binding of TAZ with -TrCP.
To confirm that Ser-311 in TAZ is indeed phosphorylated by
LATS in vivo, we generated Ser-311 phosphospecific antibody.
In vitro phosphorylationwas performed to test the specificity of
the antibody. Our data showed that incubation with LATS2
WT but not K/R mutant led to a dramatic increase of Ser-311
phosphorylation as detected by the phosphoSer-311 antibody
(Fig. 2F). S311A mutant abolished the reactivity by the phos-
phoSer-311 antibody, supporting the specificity of this anti-
body. Taking the advantage of this reagent, we examined TAZ
phosphorylation by LATS in the cell. We observed a basal level
of Ser-311 phosphorylation and a substantial increase of Ser-
311 phosphorylation when LATS2 WT, but not K/R mutant,
was co-transfected (Fig. 2G). As expected, S311A abolished rec-
ognition by the phosphoantibody. In addition, we tested the
effect of MST/LATS on the interaction between TAZ and
-TrCP. MST2/LATS2 co-transfection significantly increased
the interaction between TAZ and -TrCP, whereas co-trans-
fection of LATS2 K/R decreased TAZ interaction with -TrCP
(Fig. 2H). Taken together, these results demonstrate that phos-
phorylation of Ser-311 in TAZ is important for its binding with
-TrCP.
The Hippo pathway has been implicated in cell contact inhi-
bition. We determined TAZ protein levels of cells at different
density. As expected, TAZ protein levels decreased at high cell
density while the TAZ Ser-311 phosphorylation, as detected by
the phosphoantibody, was not significantly decreased (Fig. 2I),
indicating that the relative phosphorylation of TAZ Ser-311
was increased at high cell density. These results are consistent
with a role of the Hippo pathway in regulating TAZ Ser-311
phosphorylation and stability.
TAZ is localized in both nucleus and cytoplasm. Lats depen-
dent phosphorylation promotes cytoplasmic localization. We
examined if TAZ stability is affected by subcellular localization.
Leptomycin B, which blocks nuclear export, was used to treat
cells and TAZ stability was determined. We found that lepto-
mycin B treatment resulted in a detectable increase of TAZ
stability both in Hela and MCF10A cells (Fig. 2J). These data
suggest that the nuclear form, and possibly the unphosphory-
lated form, of TAZ might be more stable.
Casein Kinase I Cooperates with LATS to Phosphorylate TAZ
and Regulate -TrCP Binding—Ser-314 in the phosphodegron
is important in mediating TAZ binding with -TrCP, but does
not fit LATS recognition consensus and therefore, is unlikely to
be phosphorylated by LATS (Fig. 2A). We speculate that TAZ
phosphorylation at Ser-311 by LATS promotes the subsequent
phosphorylation of Ser-314 by another kinase. Casein kinase 1
(CK1), recognizes substrate phosphorylation often requires the
priming phosphorylation at position -3. We tested IC261, a
CK1/ specific inhibitor (30), and found that IC261 strongly
blocked the interaction between TAZ and -TrCP (Fig. 3A).
We directly tested the function of CK1 by co-transfection and
found that co-expression of CK1 or a constitutive active
mutant CK1R178C (31) significantly increased the interaction
betweenTAZand-TrCP (Fig. 3B).We also examinedwhether
CK1 could bind with TAZ in co-IP and found that TAZ was
readily detected in CK1 immunocomplex (Fig. 3C). Together
the above data indicate that CK1/ may be responsible for
Ser-314 phosphorylation.
We then investigated the interdependent relationship of
LATS and CK1 on promoting the interaction between TAZ
and -TrCP. Expression of the LATS K/R mutant significantly
blocked the stimulating effect of CK1 on the interaction
betweenTAZand-TrCP (Fig. 3D). Furthermore, using IC261,
we found that inhibition of CK1/ decreased the TAZ binding
to -TrCP even in the presence of LATS co-expression (Fig.
3E). Treatment with D4476, another CK1 inhibitor (32), simi-
larly inhibited the interaction between TAZ and -TrCP, sup-
porting the importance of CK1 activity forMST/LATS to pro-
mote TAZ binding with -TrCP (Fig. 3E).
To directly test the sequential phosphorylation model, we
performed in vitro kinase assay. The purified His-tagged
recombinantWTandmutant TAZwere incubatedwith immu-
noprecipitated LATS2 in the presence of cold ATP and then
LATS2was removed. The efficient removal ofHA-LATS2 from
the first kinase reactions was confirmed by HA Western blot
(Fig. 3F). Consistently, no 32P incorporation was detected if
CK1was not added in the second kinase reaction. The LATS2-
phosphorylated TAZ was then phosphorylated by immuno-
precipitated CK1 in the presence of [32P]ATP, followed by
autoradiography. We observed that CK1 could potently
phosphorylate TAZ in vitro if TAZ was prior-treated with
LATS2 (Fig. 3F). Without pre-phosphorylation by LATS2,
however, TAZ could not be phosphorylated by CK1. Further-
more, both S311A and S314A mutants abolished TAZ phos-
phorylation by CK1 (Fig. 3F). We conclude from these results
that TAZ phosphorylation by CK1 at Ser-314 is dependent on
a prior phosphorylation at Ser-311 by LATS.
LATS and CK1 Promotes TAZ Degradation—To test the
functional significance of Ser-311 phosphodegron in TAZ
stability regulation, we established stable MCF10A cell pools
expressing TAZ WT, S311A, S314A, and DG, and deter-
mined the TAZ protein stability. We observed that TAZWT
rapidly disappeared when protein synthesis was inhibited (Fig.
4A). In contrast, both S311A and S314Amutants were dramat-
ically stabilized (Fig. 4A). Similarly, DGmutation also stabilized
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TAZ. Interestingly, we observed the similar phenomena in
C3H10T1/2 cells stably expressing TAZWT, TAZS311A,
TAZS3114A, and TAZDG (supplemental Fig. S3). Consistently,
ectopic expression of LATS2 and/or CK1 decreased the steady
state level of TAZWT, but had little effect on that of TAZS311A,
TAZS314A, or TAZDGmutants (Fig. 4B). The protein level of the
co-transfected GFP was not affected. These results further
support the importance of the C-terminal phosphodegron in
regulating TAZ degradation in response to LATS and CK1.
Consistently, treatment of cells with IC261 also increased
endogenous TAZ protein levels (Fig. 4C). Furthermore,
IC261 treatment increased the steady state levels of TAZ
WT, but had little effect on that of S311A, 314A, or DG
mutant (Fig. 4D). Collectively, we conclude that LATS and
CK1 promote TAZ degradation via phosphorylation of the
C-terminal phosphodegron.
TAZ Ubiquitylation Is Promoted by LATS2, CK1, and
SCF-TrCP—We next determined the effect of Ser-311 phos-
phorylation by LATS on TAZ ubiquitylation in vivo. Prior to
the analysis of TAZ ubiquitylation, cells were treated with
MG132, to enrich ubiquitylated proteins. Co-expression of
TAZ with LATS, -TrCP, and CUL1 resulted in the detection
FIGURE 3. Casein kinase I cooperates with LATS to regulate the interaction between TAZ and -TrCP. A, IC261 treatment disrupts the interaction between
TAZ and -TrCP. The indicated plasmids were co-transfected and cells were treated with or without IC261, which is a CKI/ specific inhibitor. The interaction
between TAZ and -TrCP was analyzed by co-IP followed by WB. B, CK1 promotes the interaction between TAZ and -TrCP. The indicated plasmids were
co-transfected. The association between TAZ and -TrCP was examined by co-IP. R178C is an active mutant of CKI. C, association between CK1 and TAZ. CKI
was co-transfected with or without TAZ. co-IP was performed to examine the interaction between TAZ and CKI. D, kinase inactive LATS2 mutant blocks the
interaction between TAZ and -TrCP induced by CK1. The indicated plasmids were co-transfected into HEK293 cells. Interaction between TAZ and -TrCP was
analyzed by co-IP. E, CK1 activity is required for Mst2/LATS2 to stimulate the interaction between TAZ and -TrCP. The indicated plasmids were co-transfected,
and cells were treated with or without IC261 or D4476. The interaction between TAZ and -TrCP was analyzed by co-IP. F, phosphorylation of TAZ S314 by CKI
requires LATS2 priming phosphorylation. His-TAZ WT or mutants were expressed and purified from E. coli. The purified TAZ was incubated with HA-LATS2
immunoprecipitated from transfected HEK293T cells, in the presence of cold ATP. HA-LATS2 was removed from the kinase reaction. The prime phosphorylated
His-TAZ was then incubated with Myc-CK1 immunoprecipitated from transfected HEK293T cells, in the presence of radioactive ATP. Phosphorylation of TAZ
by CKI was detected by incorporation of 32P. His-TAZ input was shown by Coomassie Blue staining (bottom panel).
FIGURE 4. LATS and CK1 promote TAZ degradation via the C-terminal phosphodegron. A, Ser-311 and Ser-314 are important for TAZ degradation. MCF10A
cells stably expressing TAZWT, TAZS311A, TAZS3114A, and TAZDG were chased with CHX treatment as indicted. TAZ stability was determined by WB. Relative TAZ
levels were quantified by the ratio of TAZ to actin. B, Ser-311 and Ser-314 are required for TAZ destabilization by LATS and CK1. TAZ WT and different mutants
were co-transfected with or without LATS and/or CK1 as indicated. TAZ expression level was determined by WB. The co-transfected GFP and endogenous
actin were included as controls. C, CK1 inhibitor increases endogenous TAZ protein levels. HeLa cells were treated with or without IC261 at different doses and
time points. WB was performed to determine TAZ expression levels along the actin control. D, C-terminal phosphodegron is required for TAZ stabilization by
CK1 inhibitors. The indicated plasmids were transfected into 293T cells. Treatments with or without the IC261 were indicated. TAZ expression level was
determined by WB.
Hippo Tumor Pathway Promotes TAZ Degradation
NOVEMBER 26, 2010 • VOLUME 285 • NUMBER 48 JOURNAL OF BIOLOGICAL CHEMISTRY 37165
of characteristic incremental ladders, indicative of polyubiqui-
tylated species (Fig. 5A). In fact, co-expression of LATS2 alone
also induced a small, but detectable, increase of ubiquitylated
TAZ (comparing lanes 2 and 3, Fig. 5A). Omitting -TrCP and
CUL1 resulted in a substantial decrease of polyubiquitylated
TAZ (compare lanes 3 and 4), demonstrating the dependence
of TAZ polyubiquitylation on SCF-TrCP. TAZ mutants of
S311A, S314A, and DG all reduced the polyubiquitylation to
nearly undetectable low level, consistent with the functional
dependence of TAZ ubiquitylation on the phosphorylation by
LATS and CK1 and the integrity of C-terminal phosphode-
gron. The high molecular weight ladders were dramatically
diminished in the absence of MG132 (supplemental Fig. S4),
demonstrating polyubiquitylation and proteasome-dependent
degradation of TAZ in vivo.
In vitro ubiquitylation experiments were performed to
directly test the role of LATS2, CK1, the phosphodegron, and
SCF-TrCP complex in TAZ ubiquitylation. Purified TAZ (from
E. coli) was incubated with various purified proteins (from
transfectedmammalian cells) as indicated in Fig. 5B. We found
that efficient TAZ ubiquitylation required the presence of all
components of SCF E3 ligase complex, LATS, and CK1 (Fig.
5B). When either LATS or CK1 was omitted in the reactions,
TAZ ubiquitylation was considerably reduced. These data pro-
vide direct biochemical evidence that LATS and CK1 are key
regulators of TAZ ubiquitylation by SCF-TrCP. S311A, S314A,
and DG all significantly reduced in vitro TAZ ubiquitylation
(Fig. 5B). These results support a model that the sequential
phosphorylation of Ser-311 and Ser-314 by LATS and CK1 is
essential for SCF-TrCP-mediated TAZ ubiquitylation and
degradation.
The C-terminal Phosphodegron Regulates TAZ Biological
Functions—TAZ is known to induce EMT and promote cell
proliferation. To determine the functional significance of
C-terminal phosphodegron, we established MCF10A cells sta-
bly expressing different TAZ mutants. The control MCF10A
cells grew in cluster, typical for epithelial cells, while the TAZ-
expressing cells displayed a loss of cell-cell contact and were
scattered (Fig. 6A). TAZ expression also induced stress fiber
formation. We found that TAZ-S311A was more potent than
the wild type TAZ to promote EMT morphological changes in
MCF10A cells (Fig. 6A). Western blotting for EMT markers
also supports that the phosphorylation mutant TAZ caused a
stronger induction of vimentin, a marker for mesenchymal
cells, and a stronger reduction of E-cadherin, a marker for epi-
thelial cells (Fig. 6B).We also determined cell proliferation. The
TAZ S311Amutant caused a slightly increase in cell proliferation
than thewild-typeTAZ inNIH3T3 cells (supplemental Fig. S5).
Furthermore, cell migration was determined by wound healing
assays. Expression of the TAZ phosphodegron mutant stimu-
lated cell migration more potently than expression of the wild-
FIGURE 5. LATS2 and CK1 promote TAZ ubiquitylation by SCF-TrCP.
A, LATS and SCF-TrCP E3 ligase promotes TAZ ubiquitylation depending on
the C-terminal phosphodegron. FALG-TAZ was co-transfected with various
plasmids as indicated. FLAG-TAZ was immunoprecipitated and ubiquityla-
tion of the precipitated TAZ was determined by WB for the co-transfected
HA-ubiquitin or FLAG-TAZ. TAZ S311A, S314A, and DG mutants were also
tested for in vivo ubiquitylation. B, in vitro ubiquitylation of TAZ by SCF-TrCP E3
ligase requires LATS and CK1. HA-LATS2 and MYC-CK1 were immunopre-
cipitated from transfected 293T cells. In vitro ubiquitylation assays were per-
formed using purified His-TAZ as a substrate in the presence of various pro-
teins as indicated. Experiments with different TAZ mutants were also per-
formed (right panel). Ubiquitylation of TAZ was detected by FLAG antibody
for FLAG-Ub. His-TAZ input was shown by Coomassie Blue staining. Other
components were determined by WB as indicated.
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type TAZ did (Fig. 6C). These data show that the C-terminal
phosphodegron negatively regulate TAZ biological functions.
We also investigated the activity of TAZ phosphodegron
mutant in promoting transformation. Untransformed NIH3T3
cells could not form colonies in monolayer culture while
expression of TAZ could transform NIH3T3 cells. We found
that the TAZ phosphodegron mutants were significantly more
active in stimulating NIH3T3 transformation than the wild-
typeTAZ (Fig. 6D). Together, the above data demonstrate a key
role of the phosphodegrons in regulating the physiological
function of TAZ.
DISCUSSION
In this report, we show that TAZ protein stability is con-
trolled byC-terminal phosphodegron that is phosphorylated by
LATS and CK1, then recognized by the F-box protein, -TrCP,
and subsequent ubiquitylated by the SCF-TrCP E3 ligase. Our
study reveals a molecular mechanism of the Hippo pathway in
regulating TAZ degradation in addition to regulating TAZ sub-
cellular localization.
As a transcription co-activator, TAZ must enter the nucleus
in order to promote gene expression. We previously demon-
FIGURE 6. Phosphodegron mutants promote TAZ function. A, TAZ degradation mutants induce a stronger morphological change (upper panel) and altered
actin organization in MCF10A cells (lower panel). Phase-contrast images of MCF10A cells expressing vector, TAZ and TAZS311A are shown. Cells were stained
with rhodamine-conjugated phalloidin. B, TAZ degradation mutants are more potent in inducing EMT in MCF10A cells. Cell lysates from MCF10A cells
expressing vector, TAZ and TAZS311A were probed for epithelial marker and mesenchymal marker as indicated. C, TAZ degradation mutants stimulate cell
migration. MCF10A cells expressing vector, TAZ and TAZS311A were analyzed for migration by a wound healing assay. D, transformation of NIH 3T3 cells by TAZ
degradation mutants. 5  103 NIH3T3 cells stably expressing vector, TAZ and TAZS311A were cultured in soft agar for 14 days before colonies were counted.
Colonies were then visualized by crystal violet staining and counted.
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strated that the Hippo pathway inhibits TAZ by promoting
cytoplasmic localization via Ser-89 phosphorylation, which
generates a 14-3-3 binding site (15). This provides amechanism
of spatial separation of TAZ by sequestering it away from its
nuclear target transcription factors, such as TEAD (26, 33). In
this study we revealed another mechanism, SCF-TrCP-medi-
ated ubiquitylation and 26 S proteasome-dependent degrada-
tion, for the regulation of TAZ by the Hippo pathway via pro-
tein stability control.
We found that LATS phosphorylates TAZon Ser-311, which
primes TAZ for phosphorylation on Ser-314 by CK1. Phos-
phorylation of Ser-314 produces a functional phosphodegron
that is recognized by -TrCP, resulting in subsequent TAZ
ubiquitylation and degradation. In contrast to the spatial regu-
lation of TAZ via nuclear-cytoplasmic shuttling that is reversi-
ble and probably represents a short-term inhibition in response
to the LATS activation, the SCF-TrCP-mediated ubiquitylation
provides a mechanism of irreversible inhibition and is more
likely employed by the cells for a long-term growth arrest.
One noticeable difference between these two mechanisms is
that LATS-mediated Ser-89 phosphorylation alone is sufficient
to promote cytoplasmic retention of TAZ, while SCF-TrCP-
mediated ubiquitylation requires sequential phosphorylation of
the C-terminal phosphodegron by both LATS and CK1. Only
when both LATS and CK1 are activated, can TAZ degradation
be triggered. We speculate that such a requirement of sequen-
tial phosphorylation sets a high stringency before the irrevers-
ible degradation can occur.
Our data show that activation of the C-terminal phosphode-
gron requires the sequential phosphorylation by LATS and
CK1. CK1 kinase recognizes unique substrate specificity as p(S/
T)-X(1–2)-(S/T), which requires preceding phosphorylation of
residue at the -2 or -3 position of the target residue. The coor-
dinated phosphorylation of the C-terminal phosphodegron by
LATS and CK1 provides a biochemical mechanism for signal
integration. TAZ ubiquitylation cannot be initiated unless both
LATS and CK1 are active. LATS kinase is activated by high cell
density while the signal that is mediated by CK1 to destabilize
TAZ remains to be determined. Consistent with our model,
mutation of either the LATS phosphorylation site Ser-311 or
the CK1 phosphorylation site Ser-314 stabilizes TAZ protein.
In fact, mutation of either Ser-311 or Ser-314 activates TAZ as
the mutant TAZ is more potent than theWT in inducing EMT
and transformation.
YAP is a transcription co-activator related to TAZ and also
acts downstream of the Hippo pathway. YAP also contains a
C-terminal phosphodegron that is regulated in a manner simi-
lar to TAZ (34). The biological functions of the two proteins are
not redundant. For example, the Yap knock-out mice are early
embryonic lethal while Taz knock-out mice go through normal
development but develop cystic renal disease (22, 23, 35). Fur-
thermore, elevated protein levels of both YAP and TAZ have
been found in human cancers, but with clear organ and tissues
specificities. For example, elevated YAP protein has been found
in liver and prostate cancers while high TAZ protein is associ-
ated with breast cancer. The Hippo pathway has been shown to
promote YAP degradation in a manner similar to TAZ (34),
therefore, revealing a commonmechanismof phosphorylation-
coupled degradation in regulation of Lats targets.
In summary, we have demonstrated that TAZ stability is
controlled by C-terminal phosphodegron recognized by the
SCF-TrCP E3 ligase. Activation of the C-terminal phosphode-
gron depends on the sequential phosphorylation by LATS and
CK1. Our studies provide new insights into the mechanism of
TAZ overexpression in human cancer.
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